PROGENICS PHARMACEUTICALS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - continued

(amounts in thousands, except per share amounts or as otherwise noted)

7. Restructuring

We incurred a $0.4 million headcount reduction restructuring obligation in the first quarter of 2014, which was fully paid as of the end of the third quarter 2014. A first quarter 2013 headcount reduction resulted in a $1.5 million restructuring obligation paid that year. During the second quarter of 2013, we incurred other exit and contract termination costs, including in connection with termination of a Molecular facilities lease ($0.9 million) and amendment and consolidation of the Company's facilities lease ($0.5 million).

Activity in the restructuring accrual, which is included in accounts payable and accrued expenses in our Consolidated Balance Sheets, and in research and development and general and administrative expenses in the Consolidated Statements of Operations, is specified below.

	Severance and Related Benefits			Other Exit Costs			Contract Termination Costs			Total Restructuring Accrual
Balance at December 31, 2011	$	571		$	6		$	154		$	731
Additions, net		1,905			184			3			2,092
Payments		(1,663	)		(190	)		(157	)		(2,010	)
Balance at December 31, 2012		813			-			-			813
Additions, net		1,492			15			1,359			2,866
Payments		(2,305	)		(15	)		(1,359	)		(3,679	)
Balance at December 31, 2013		-			-			-			-
Additions, net		359			-			-			359
Payments		(359	)		-			-			(359	)
Balance at December 31, 2014	$	-		$	-		$	-		$	-